Alto Neuroscience Inc (NASDAQ: ANRO) is a clinical-stage biopharmaceutical company developing precision psychiatry drug candidates using a biomarker-driven platform. The company generates no product revenue as of its 10-K filed 2026-03-16, as its pipeline remains in clinical development and no candidates have received regulatory approval. Alto's approach centers on matching patients to treatments through proprietary data collection systems designed to identify biological markers relevant to psychiatric conditions. The company relies on third-party contract manufacturers for clinical trial supply and has entered into a loan and security agreement with K2 HealthVentures LLC (dated December 16, 2022, amended January 13, 2025) as a debt financing arrangement. An exclusive license agreement with The Board of Trustees of the Leland Stanford Junior University (dated December 6, 2019, as amended) underlies a portion of its intellectual property. Alto has received Fast Track Designation from the FDA for at least one product candidate, enabling more frequent FDA interactions and potential rolling NDA review.

Revenue model

Alto Neuroscience has no approved products and generates no product revenue as of the 10-K filed 2026-03-16. The company is funded through equity financing and debt, including a loan facility with K2 HealthVentures LLC.

Products and services

Clinical-stage psychiatric drug candidates developed using a proprietary biomarker-based precision psychiatry platform and internal data collection systems. At least one product candidate holds FDA Fast Track Designation as of the 10-K filed 2026-03-16. No products are approved or commercialized.

Customers and end markets

Target end markets are physicians, patients, and third-party payors in psychiatry. Commercialization, if achieved, would depend on coverage and reimbursement from governmental programs such as Medicare and Medicaid and private insurers. No commercial customers exist as of the 10-K filed 2026-03-16.

Value-chain role

Drug developer relying on third-party contract manufacturers for clinical supply, contract research organizations for trial conduct, and licensed intellectual property from Stanford University. Alto does not manufacture its own drug candidates.

Geographic exposure

Incorporated and operating in the United States, subject to U.S. federal and state regulations including FDA oversight, HIPAA, FTC Act, and FCPA as disclosed in the 10-K filed 2026-03-16.

Source: SEC 10-K, filed 2026-03-16

Industry: Pharmaceutical Preparations Peers: Aquestive Therapeutics Inc Atea Pharmaceuticals Inc Biote Corp Eli Lilly and Co Esperion Therapeutics Inc EyePoint Inc Revance Therapeutics, Inc. Xeris Biopharma Holdings Inc